Sonova (OTCMKTS:SONVY) vs. Microbot Medical (NASDAQ:MBOT) Critical Comparison

Sonova (OTCMKTS:SONVY) and Microbot Medical (NASDAQ:MBOT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Risk and Volatility

Sonova has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500.

Profitability

This table compares Sonova and Microbot Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sonova	N/A	N/A	N/A
Microbot Medical	N/A	-37.06%	-34.44%

Insider and Institutional Ownership

0.0% of Sonova shares are held by institutional investors. Comparatively, 16.3% of Microbot Medical shares are held by institutional investors. 0.0% of Sonova shares are held by insiders. Comparatively, 4.7% of Microbot Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Sonova and Microbot Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonova	$4.36 billion	3.54	$610.01 million	N/A	N/A
Microbot Medical	N/A	N/A	-$11.44 million	($0.45)	-4.60

Sonova has higher revenue and earnings than Microbot Medical.

Analyst Ratings

This is a summary of recent recommendations for Sonova and Microbot Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonova	3	4	1	1	2.00
Microbot Medical	1	1	2	0	2.25

Microbot Medical has a consensus target price of $8.75, suggesting a potential upside of 322.71%. Given Microbot Medical’s stronger consensus rating and higher possible upside, analysts plainly believe Microbot Medical is more favorable than Sonova.

Summary

Sonova beats Microbot Medical on 6 of the 11 factors compared between the two stocks.

About Sonova

Sonova Holding AG manufactures and sells hearing care solutions for adults and children in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It operates through two segments, Hearing Instruments and Cochlear Implants segments. The Hearing Instruments segments engages in the design, development, manufacture, distribution, and service of hearing instruments and related products, as well as wireless headsets, speech-enhanced hearables, and audiophile headphones under the Phonak, Unitron, Hansaton, and Sennheiser brand names; and audiological care services under the AudioNova, Audium, Audition Santé, Boots Hearingcare, Connect Hearing, Geers, Hansaton, Lapperre, Schoonenberg, and Triton Hearing brands. The Cochlear Implants segment is involved in the design, development, manufacture, distribution, and service of hearing implants and related products under the Advanced Bionics brand. The company sells its products through independent distributors; and provides hearing care services through a network of stores and clinics. The company was formerly known as Phonak Holding AG and changed its name to Sonova Holding AG in August 2007. Sonova Holding AG was founded in 1947 and is headquartered in Stäfa, Switzerland.

About Microbot Medical

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.